Convergent Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Convergent Therapeutics's estimated annual revenue is currently $1.4M per year.
- Convergent Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Convergent Therapeutics has 18 Employees.
- Convergent Therapeutics grew their employee count by 200% last year.
Convergent Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | COO | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Chief Business Advisor | Reveal Email/Phone |
7 | SVP & Head, Global Development | Reveal Email/Phone |
8 | VP Radiopharmaceutical Sciences | Reveal Email/Phone |
9 | SVP Clinical Development | Reveal Email/Phone |
10 | Director Finance | Reveal Email/Phone |
Convergent Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Convergent Therapeutics?
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$1.4M
Revenue (est)
200%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.1M | 18 | -10% | $161M |
#2 | $3.5M | 18 | N/A | N/A |
#3 | $1.6M | 18 | N/A | N/A |
#4 | $2.5M | 18 | -14% | N/A |
#5 | $3.5M | 18 | -40% | N/A |